| 1.25 -0.21 (-14.38%) | 12-15 15:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.67 |
1-year : | 1.86 |
| Resists | First : | 1.43 |
Second : | 1.6 |
| Pivot price | 1.31  |
|||
| Supports | First : | 1.16 |
Second : | 0.97 |
| MAs | MA(5) : | 1.46 |
MA(20) : | 1.29 |
| MA(100) : | 1.42 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 55.8 |
D(3) : | 73.9 |
| RSI | RSI(14): 44.1 |
|||
| 52-week | High : | 3.19 | Low : | 1.16 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RFL ] has closed above bottom band by 38.3%. Bollinger Bands are 78.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.47 - 1.48 | 1.48 - 1.49 |
| Low: | 1.22 - 1.22 | 1.22 - 1.23 |
| Close: | 1.24 - 1.25 | 1.25 - 1.26 |
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Tue, 02 Dec 2025
Rafael Holdings issues warrants in connection with Cyclo Therapeutics merger - Investing.com
Tue, 02 Dec 2025
Rafael Holdings Issues Warrants Post-Merger with Cyclo Therapeutics - TradingView — Track All Markets
Wed, 29 Oct 2025
Rafael Holdings Appoints Alan Grayson to Board - The Globe and Mail
Fri, 26 Sep 2025
One Rafael Holdings Insider Raised Stake By 1,810% In Previous Year - simplywall.st
Thu, 12 Jun 2025
Rafael Holdings Up 29%, Insider Buyers Are Up 61% - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Real Estate
|
|
|
Industry:
Real Estate - Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 3.181e+007 (%) |
| Held by Institutions | 37.7 (%) |
| Shares Short | 62 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.113e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 225.4 % |
| Return on Equity (ttm) | -20.4 % |
| Qtrly Rev. Growth | 1.03e+006 % |
| Gross Profit (p.s.) | 126.81 |
| Sales Per Share | -54.35 |
| EBITDA (p.s.) | 1.33768e+006 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.52 |
| Dividend | 0 |
| Forward Dividend | 72740 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|